spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Envigo launches PATHWAY an optimized safety assessment solution to enable first in human clinical trials

Envigo


11 March 2019, East Millstone, N.J. – Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. PATHWAY is designed to manage the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers by integrating safety assessment study types and bioanalytical support with scientific and regulatory consulting, program design and project management.

The decision to develop the PATHWAY solution was made in order to help our customers navigate the increased scientific and regulatory complexity facing advanced therapies going through safety assessment. The intricacy of design and management of these critical non-clinical programs, and the level of interaction with regulatory bodies required, raises the risk of introducing delays and costs to development programs. PATHWAY has been designed to leverage Envigo’s capacity, capabilities and experience in the field to optimize safety assessment programs and deliver translational biology insights to prepare customers for first-in-human clinical trials.

“Our deep expertise in the complex fields of biologics and advanced therapies adds particular value to our customers with drug development programs in these growing categories. On our customers’ behalf, we frequently work with regulators to determine the most appropriate interpretation of regulatory guidance as it applies to a specific therapeutic,” commented Lee Coney, Envigo’s Chief Scientific Officer.

“PATHWAY makes full use of our beginning-to-end understanding of the safety assessment process, and optimizes the journey to first-in-human studies. Experience of designing and conducting studies in a wide range of therapeutic modalities, and in working with regulatory agencies around the world, means we are able to anticipate the needs of a program at design stage, plan studies accordingly, and manage an optimal timeline of study execution,” Lee Coney added.

With harmonized facilities with AAALAC accreditation in Europe and North America, Envigo further seeks to optimize safety assessment programs by ensuring studies are carried out at centers of excellence and where capacity permits the earliest possible start date for commencing work.

About Envigo
Envigo provides mission-critical products and research services for biopharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. Our company is founded on the principle that research partnerships depend on unmatched expertise, unwavering dedication to customer service and shared goals. With more than 3,000 employees worldwide, we are committed to helping customers realize the full potential of their research and products as we work together to build a healthier and safer world.

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on +44 (0) 203 735 8167 or e-mail: t.jervis@defacto.com.

Read more at envigo.com

Envigo contacts:
Katie Bramwell +44 (0) 1480 892748 katie.bramwell@envigo.com
Paul Surdez +1 732 873 6682 paul.surdez@envigo.com
phone +44 (0)1480 892 000
web www.envigo.com
email Woolley Road Alconbury Huntingdon, Cambridgeshire PE28 4HS
 
Print this page
Send to a friend
   
spacer
News and Press Releases

A New Era for Faster s.r.l. Air Safety Products in the UK.

In November 2018, Biopharma Group became the exclusive distributor of Italian brand, Faster S.r.l.’s clean air and laboratory range of products within mainland UK.
More info >>


White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

Industry Events

Respiratory Drug Delivery (RDD®) Europe 2019

7-10 May 2019, Estoril Congress Center, Lisbon

Respiratory Drug Delivery (RDD®) Europe 2019 connects emerging and high-level scientists, academics, industrial and regulatory specialists, and clinicians. It is a must-attend conference for companies involved in research, development, testing or marketing of medicines, devices and services associated with pulmonary or nasal pharmaceutical products. This year, RDD Europe 2019 will be held in Estoril (Lisbon), Portugal, May 7-10, 2019, and, as in previous years is jointly organized by RDD Online and Aptar Pharma.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement